Logo image of DRCT

DIRECT DIGITAL HOLDINGS IN-A (DRCT) Stock Fundamental Analysis

NASDAQ:DRCT - Nasdaq - US25461T1051 - Common Stock - Currency: USD

0.49  0 (0%)

Fundamental Rating

2

Overall DRCT gets a fundamental rating of 2 out of 10. We evaluated DRCT against 96 industry peers in the Media industry. DRCT has a bad profitability rating. Also its financial health evaluation is rather negative. DRCT has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DRCT has reported negative net income.
DRCT had a negative operating cash flow in the past year.
In the past 5 years DRCT reported 4 times negative net income.
In multiple years DRCT reported negative operating cash flow during the last 5 years.
DRCT Yearly Net Income VS EBIT VS OCF VS FCFDRCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

DRCT's Return On Assets of -23.98% is on the low side compared to the rest of the industry. DRCT is outperformed by 78.13% of its industry peers.
Industry RankSector Rank
ROA -23.98%
ROE N/A
ROIC N/A
ROA(3y)-6.66%
ROA(5y)-5.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRCT Yearly ROA, ROE, ROICDRCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

Looking at the Gross Margin, with a value of 27.92%, DRCT is doing worse than 65.63% of the companies in the same industry.
DRCT's Gross Margin has declined in the last couple of years.
DRCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.71%
GM growth 5YN/A
DRCT Yearly Profit, Operating, Gross MarginsDRCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

0

2. Health

2.1 Basic Checks

DRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRCT has been increased compared to 1 year ago.
Compared to 1 year ago, DRCT has a worse debt to assets ratio.
DRCT Yearly Shares OutstandingDRCT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
DRCT Yearly Total Debt VS Total AssetsDRCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

DRCT has an Altman-Z score of 0.20. This is a bad value and indicates that DRCT is not financially healthy and even has some risk of bankruptcy.
DRCT has a worse Altman-Z score (0.20) than 67.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC11.64%
DRCT Yearly LT Debt VS Equity VS FCFDRCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

DRCT has a Current Ratio of 0.64. This is a bad value and indicates that DRCT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.64, DRCT is not doing good in the industry: 80.21% of the companies in the same industry are doing better.
A Quick Ratio of 0.64 indicates that DRCT may have some problems paying its short term obligations.
DRCT has a Quick ratio of 0.64. This is amonst the worse of the industry: DRCT underperforms 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.64
DRCT Yearly Current Assets VS Current LiabilitesDRCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

DRCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2903.74%.
Looking at the last year, DRCT shows a very negative growth in Revenue. The Revenue has decreased by -60.35% in the last year.
The Revenue has been growing by 17.76% on average over the past years. This is quite good.
EPS 1Y (TTM)-2903.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.09%
Revenue 1Y (TTM)-60.35%
Revenue growth 3Y17.76%
Revenue growth 5YN/A
Sales Q2Q%-63.38%

3.2 Future

Based on estimates for the next years, DRCT will show a very strong growth in Earnings Per Share. The EPS will grow by 42.17% on average per year.
Based on estimates for the next years, DRCT will show a very strong growth in Revenue. The Revenue will grow by 24.47% on average per year.
EPS Next Y106.22%
EPS Next 2Y42.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.42%
Revenue Next 2Y24.47%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DRCT Yearly Revenue VS EstimatesDRCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
DRCT Yearly EPS VS EstimatesDRCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

DRCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
DRCT is valuated reasonably with a Price/Forward Earnings ratio of 8.01.
80.21% of the companies in the same industry are more expensive than DRCT, based on the Price/Forward Earnings ratio.
DRCT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.43.
Industry RankSector Rank
PE N/A
Fwd PE 8.01
DRCT Price Earnings VS Forward Price EarningsDRCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRCT Per share dataDRCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DRCT's earnings are expected to grow with 42.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DRCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIRECT DIGITAL HOLDINGS IN-A

NASDAQ:DRCT (5/21/2025, 10:48:45 AM)

0.49

0 (0%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)10-13 2025-10-13
Inst Owners4.4%
Inst Owner Change6.71%
Ins Owners6.97%
Ins Owner Change-5.64%
Market Cap9.27M
Analysts80
Price Target8.16 (1565.31%)
Short Float %8.06%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-814.97%
Min EPS beat(2)-1629.45%
Max EPS beat(2)-0.49%
EPS beat(4)0
Avg EPS beat(4)-477.1%
Min EPS beat(4)-1629.45%
Max EPS beat(4)-0.49%
EPS beat(8)1
Avg EPS beat(8)-214.09%
EPS beat(12)3
Avg EPS beat(12)-136.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-60.32%
Min Revenue beat(2)-85.1%
Max Revenue beat(2)-35.54%
Revenue beat(4)0
Avg Revenue beat(4)-43.93%
Min Revenue beat(4)-85.1%
Max Revenue beat(4)-6.91%
Revenue beat(8)3
Avg Revenue beat(8)-13%
Revenue beat(12)6
Avg Revenue beat(12)-1.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)52.38%
EPS NQ rev (1m)98.78%
EPS NQ rev (3m)99.31%
EPS NY rev (1m)179.55%
EPS NY rev (3m)112.87%
Revenue NQ rev (1m)-42.19%
Revenue NQ rev (3m)-33.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.01
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)0.06
Fwd EY12.49%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS3.29
BVpS-0.26
TBVpS-1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.98%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.92%
FCFM N/A
ROA(3y)-6.66%
ROA(5y)-5.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.71%
GM growth 5YN/A
F-Score2
Asset Turnover2.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.71%
Cap/Sales 0.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.64
Altman-Z 0.2
F-Score2
WACC11.64%
ROIC/WACCN/A
Cap/Depr(3y)14.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2903.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-59.09%
EPS Next Y106.22%
EPS Next 2Y42.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-60.35%
Revenue growth 3Y17.76%
Revenue growth 5YN/A
Sales Q2Q%-63.38%
Revenue Next Year39.42%
Revenue Next 2Y24.47%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-503.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.08%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-464.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-438.08%
OCF growth 3YN/A
OCF growth 5YN/A